- Home
- NOM vs ALGS Comparison
NOM vs ALGS Comparison
Compare NOM & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOM
- ALGS
- Stock Information
- Founded
- NOM 1993
- ALGS 2018
- Country
- NOM United States
- ALGS United States
- Employees
- NOM N/A
- ALGS 68
- Industry
- NOM Investment Managers
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- NOM Finance
- ALGS Health Care
- Exchange
- NOM Nasdaq
- ALGS Nasdaq
- Market Cap
- NOM 25.1M
- ALGS 71.0M
- IPO Year
- NOM N/A
- ALGS 2020
- Fundamental
- Price
- NOM $10.68
- ALGS $19.03
- Analyst Decision
- NOM
- ALGS Strong Buy
- Analyst Count
- NOM 0
- ALGS 1
- Target Price
- NOM N/A
- ALGS $75.00
- AVG Volume (30 Days)
- NOM 6.9K
- ALGS 562.3K
- Earning Date
- NOM 01-01-0001
- ALGS 11-06-2024
- Dividend Yield
- NOM 3.39%
- ALGS N/A
- EPS Growth
- NOM N/A
- ALGS N/A
- EPS
- NOM N/A
- ALGS N/A
- Revenue
- NOM N/A
- ALGS $5,997,000.00
- Revenue This Year
- NOM N/A
- ALGS N/A
- Revenue Next Year
- NOM N/A
- ALGS N/A
- P/E Ratio
- NOM N/A
- ALGS N/A
- Revenue Growth
- NOM N/A
- ALGS N/A
- 52 Week Low
- NOM $8.52
- ALGS $6.76
- 52 Week High
- NOM $10.48
- ALGS $30.00
- Technical
- Relative Strength Index (RSI)
- NOM 52.15
- ALGS 70.57
- Support Level
- NOM $10.63
- ALGS $14.65
- Resistance Level
- NOM $10.79
- ALGS $24.84
- Average True Range (ATR)
- NOM 0.15
- ALGS 3.00
- MACD
- NOM 0.04
- ALGS 0.59
- Stochastic Oscillator
- NOM 79.85
- ALGS 56.96
About NOM Nuveen Missouri Quality Municipal Income Fund
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in United States. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Missouri state income taxes; its secondary investment objective is the enhancement of portfolio value. The fund invests in municipal securities as well as floating rate securities as well as derivatives such as futures, options and swap contracts to the necessary extent. Nuveen Fund Advisors, LLC acts as an investment adviser of the company.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.